Global markets are being pulled in different directions by inflation data, shifting rate expectations and uneven growth across major economies, so picking individual stocks can feel confusing. The Healthy high growth potential screener cuts through this by focusing on companies where analysts see strong earnings growth over the next 3 years and balance sheets that meet clear financial health checks. That combination may appeal if you want exposure to growth while keeping an eye on risk. In this article, you will see 3 of the leading stocks from this screener and how they fit with today’s macro backdrop.

Eldorado Gold (TSX:ELD)

Overview: Eldorado Gold is a Canada based miner that focuses on producing gold, with additional silver, lead and zinc, from a portfolio of fully owned mines in Turkey, Canada and Greece, along with several development projects that can extend its life and output over time.

Operations: Eldorado Gold generates about US$2.0b from mining, exploration and development activities, with revenue mainly coming from Turkiye (US$908.3m), Canada (US$755.8m) and Greece (US$331.9m).

Market Cap: CA$10.8b

Eldorado Gold stands out in the Healthy high growth potential screener because analysts expect fast earnings and revenue growth, supported by new projects such as the Skouries copper gold mine and the ramp up of McIlvenna Bay, along with ongoing cost and efficiency work at core sites such as Kişladağ and Lamaque. At the same time, the stock screens as undervalued on cash flow and P/E signals, even after a period in which reported margins are already solid. The catch is that this growth story involves higher capital spending, external funding and execution in more complex jurisdictions, with insider selling and prior dilution raising additional questions about risk. The full picture helps explain why some investors are optimistic while others remain cautious.

Fast earnings growth expectations, fresh projects and an apparently cheap P/E and cash flow profile make Eldorado Gold look like an underappreciated rerating story, but the real twist sits in the 4 key rewards and 3 important warning signs (1 is major!)

Iovance Biotherapeutics (IOVA)

Overview: Iovance Biotherapeutics is a commercial stage biotech company that develops and sells personalized cell therapies, such as Amtagvi and Proleukin, to treat advanced melanoma and other hard to treat solid tumor cancers in the United States and internationally.

Operations: Iovance Biotherapeutics generates about US$285.6m in revenue from its autologous tumor infiltrating lymphocyte therapies and related products. Roughly US$281.0m comes from the United States and US$4.6m from the rest of the world.

Market Cap: US$1.8b

Iovance Biotherapeutics draws interest because it already has an FDA approved TIL therapy, Amtagvi, on the market. Analysts still expect high revenue and earnings growth and see the stock trading well below estimated fair value. The company is guiding to US$350 to US$370m of product revenue in 2026, yet it remains loss making and relies on external funding, so execution on commercialization and cost control is important. A broad pipeline across multiple solid tumors and recent approvals in markets like Australia indicate a larger opportunity, but prior dilution, share price volatility and funding risk mean the stock may be more suitable for investors who are comfortable with higher risk and the possibility of losses.

Iovance Biotherapeutics already has Amtagvi on the market and is guiding to US$350 to US$370m of product revenue in 2026, but the real story sits in the analyst forecasts for Iovance Biotherapeutics

Celcuity (CELC)

Overview: Celcuity is a clinical stage biotech based in Minneapolis that is developing gedatolisib, a targeted therapy aimed at treating difficult solid tumors such as hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer.

Market Cap: US$5.4b

Celcuity has quickly moved into the spotlight after the FDA fully approved REVTORPYK (gedatolisib) for HR+/HER2-, PIK3CA wild type advanced breast cancer. This gives the company its first commercial product and a foothold in what management sizes as a multi billion dollar addressable market. Analysts still see high revenue and earnings growth potential, but the stock sits at a very high P/B multiple and Celcuity remains loss making, with a Q1 2026 net loss of US$52.8m and heavy spending on trials and a 100 person sales force. Add in a US$500m convertible notes deal, prior dilution and very volatile trading, and the result is a high risk, high potential story that only comes into focus once you look closely at the full risk and reward profile.

Celcuity’s surge into a multi billion dollar breast cancer opportunity with REVTORPYK, a US$5.4b valuation and heavy trial and sales spend raises a sharper question about the true balance of risk and upside in the 3 key rewards and 3 important warning signs (1 is major!)

The stocks in this article are only a starting point. The full Healthy high growth potential screener uncovered 1,503 more companies with similarly compelling stories inside the Healthy high growth potential screener. Use Simply Wall St to identify, filter and analyze the specific catalysts, financial profiles and narratives that matter most so you can focus on your highest conviction ideas.

Take Control of Your Investment Journey

If Iovance Biotherapeutics or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Picks?

Fresh ideas can move fast, and the stocks that look quiet today can build breakout momentum before most investors even notice. Scan these curated lists before the window drops and consider your options.

• Spot companies quietly gaining strength with a list of solid balance sheet and fundamentals (11 results) so you are looking at businesses that already have the financial foundations in place.
• Explore sector shifts by checking the 34 power grid technology and infrastructure stocks and focus on companies tied to energy and infrastructure upgrades while they are still less widely followed.
• Identify steady compounders early by using the 10 resilient stocks with low risk scores and focus on businesses where resilience, not volatility, is the key feature.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.